Kronos Bio

Kronos Bio, Inc. is a clinical-stage biopharmaceutical, engages in the provision of discovery and development of novel cancer therapeutics products. Its pipeline includes hematologic malignancies, prostate cancer, MYC-driven cancers, and small cell/neuroendocrine cancers. The company was founded by Angela Koehler and Joshua A. Kazam in 2017 and is headquartered in San Mateo, CA.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kronos Bio, Inc. is a clinical development biopharmaceutical company. It engages in the business of developing therapeutics that target dysregulated transcription that causes cancer and other serious diseases. The company was founded by Arie S. Belldegrun, Joshua A. Kazam, David M. Tanen, and Christopher Wilfong on June 2, 2017 and is headquartered in San Mateo, CA.

SAN MATEO, Calif. and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will present a study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors from the ongoing Phase 1/2 trial, KB-0742-1001 ( NCT04718675 ), at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held from May 31 – June 4, 2024 in Chicago, Illinois and online.

Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Kronos Bio (KRON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Kronos Bio (KRON) Upgraded to Buy: What Does It Mean for the Stock?

Phase 1/2 study of KB-0742 is on track to clear 80mg four-days-on, three-days-off schedule in the third quarter of 2024; topline data from expansion cohort at this schedule expected in the first half of 2025

Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results

Kronos Worldwide KRO (NYSE: KRO), a titanium dioxide pigments (TiO2) producer and marketer, has gained around 15% in a week, considerably outperforming the broader Russell 2000 index which remains down by 0.2% over the same period. So what's driving the recent surge in the stock?

How Does Kronos Stock Look After Its 15% Rise Last Week?

Company to assess KB-0742 at planned new dose schedule in ongoing phase 1/2 study; topline data from expansion cohort at new dose schedule expected in the first half of 2025

Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that three abstracts have been selected for presentation at the American Association for Cancer Research (AACR) annual meeting, being held from April 5-10, 2024 in San Diego, California.

Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting

SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced participation in the 44th Annual Cowen Health Care Conference, taking place March 4-6, 2024, in Boston, Massachusetts.

Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference

Company eliminates three executive officer roles and appoints new Executive Leadership team Company eliminates three executive officer roles and appoints new Executive Leadership team

Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement

Phase 1b portion of phase 1b/2 lanraplenib study in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia completed; review of data does not support continuing to phase 2

Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate

SAN MATEO, Calif. and CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that Jorge DiMartino M.D., Ph.D., chief medical officer and executive vice president of clinical development, and Charles Lin, Ph.D., senior vice president of TRN mapping will participate in a fireside chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference on Wednesday, December 6, 2023 at 11:00 a.m. ET.

Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that Norbert Bischofberger, Ph.D., president and chief executive officer, Jorge DiMartino M.D., Ph.D., chief medical officer and executive vice president of clinical development, and Charles Lin, Ph.D., senior vice president of TRN Mapping will participate in a fireside chat at the 35th Annual Piper Sandler Healthcare Conference on Tuesday, November 28, 2023 at 4:00 p.m. ET.

Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference

Altamira Therapeutics Ltd

Fortress Biotech

Hookipa Pharma Inc

Whether you're looking at the “ Magnificent Seven stocks ,” or just the next round of penny stocks to watch, news & company events can quickly sway sentiment. This week is a short holiday week with Thursday's Thanksgiving Holiday and one of the “Magnificent Seven” could become a major catalyst.

Best Penny Stocks To Buy This Week? 4 To Watch Now

Kronos Bio, Inc. (KRON) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.57 per share a year ago.

Kronos Bio, Inc. (KRON) Reports Q3 Loss, Lags Revenue Estimates

Company presented positive preliminary data from Phase 1 dose escalation portion of  Phase 1/2 KB-0742 study at the AACR-NCI-EORTC and CTOS conferences

Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial Results

Strategic resource allocation to fully explore KB-0742's potential in both dose escalation and expansion cohorts across multiple tumor types in its ongoing Phase 1/2 study

Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 1/2 Study

Brian Van Tine, M.D., of Washington University School of Medicine, shares data  from the ongoing phase 1/2 KB-0742 clinical study that clearly corresponds with the findings from the pre-clinical studies at leading international sarcoma meeting

Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting

Brian Van Tine, M.D., of Washington University School of Medicine to share data  from the ongoing Phase 1/2 study at leading international sarcoma meeting

Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting

Demonstrated on-mechanism, single agent anti-tumor activity in heavily pre-treated patients with transcriptionally addicted solid tumors

Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC

Management to host conference call and webcast on October 13 at 4:30 PM ET with key opinion leader and KB-0742 trial investigator, Miguel Villalona-Calero, M.D., of City of Hope Management to host conference call and webcast on October 13 at 4:30 PM ET with key opinion leader and KB-0742 trial investigator, Miguel Villalona-Calero, M.D., of City of Hope

Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13

SAN MATEO, Calif. and CAMBRIDGE, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, announced that its Chief Financial Officer and Head of Corporate Development, Yasir Al-Wakeel, BM BCh, will resign from his position to pursue a new professional opportunity as the chief executive officer of a private biotechnology company. The Company has initiated a search to identify a suitable replacement for Dr. Al-Wakeel, who will remain with Kronos Bio until September 15, 2023 to ensure business continuity.

Kronos Bio Announces Departure of Chief Financial Officer and Head of Corporate Development

Kronos Bio, Inc. (KRON) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.59 per share a year ago.

Kronos Bio, Inc. (KRON) Reports Q2 Loss, Misses Revenue Estimates

Data from the Phase 1 dose escalation portion of the Phase 1/2 KB-0742 study will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October 2023

Kronos Bio Reports Recent Business Progress and Second-Quarter 2023 Financial Results

Dr. Besman brings more than 25 years of regulatory affairs and drug development experience and a track record of successfully advancing clinical programs Dr. Besman brings more than 25 years of regulatory affairs and drug development experience and a track record of successfully advancing clinical programs

Kronos Bio Names Marc Besman, Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance

SAN MATEO, Calif. and CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences:

Kronos Bio Announces Participation in Upcoming Investor Conferences

Kronos Bio, Inc. (KRON) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.65 per share a year ago.

News for Kronos Bio Stock (KRON)